Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins
暂无分享,去创建一个
G. Narasimhan | K. Mathee | Jessica Siltberg-Liberles | Janelle Nunez-Castilla | Trevor M. Cickovski | Vitalii Stebliankin | Christian A Balbin | Prabin Baral | P. Chapagain | A. Mondal | Masrur Sobhan
[1] Bjoern Peters,et al. Bioinformatic Analysis Underpinning the Frequent Occurrence of Immune Thrombocytopenic Purpura in COVID-19 Patients. , 2022, The Israel Medical Association journal : IMAJ.
[2] G. Narasimhan,et al. EMoMiS: A Pipeline for Epitope-based Molecular Mimicry Search in Protein Structures with Applications to SARS-CoV-2 , 2022, bioRxiv.
[3] Benjamin Bowe,et al. Long-term cardiovascular outcomes of COVID-19 , 2022, Nature Medicine.
[4] Bjoern Peters,et al. Lack of evidence of significant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens , 2022, eBioMedicine.
[5] K. Khunti,et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection , 2021, Nature Medicine.
[6] P. Desprès,et al. The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech) , 2021 .
[7] M. Takeda. Proteolytic activation of SARS‐CoV‐2 spike protein , 2021, Microbiology and immunology.
[8] Bosco K. Ho,et al. SARS‐CoV‐2 structural coverage map reveals viral protein assembly, mimicry, and hijacking mechanisms , 2021, Molecular systems biology.
[9] V. Khavinson,et al. Homology between SARS CoV-2 and human proteins , 2021, Scientific Reports.
[10] A. Galvani,et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis , 2021, Proceedings of the National Academy of Sciences.
[11] M. Beltramello,et al. Broad betacoronavirus neutralization by a stem helix–specific human antibody , 2021, Science.
[12] K. Kavukcuoglu,et al. Highly accurate protein structure prediction for the human proteome , 2021, Nature.
[13] Oriol Vinyals,et al. Highly accurate protein structure prediction with AlphaFold , 2021, Nature.
[14] Paul J. Birrell,et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, medRxiv.
[15] S. Li,et al. Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern , 2021, JCI insight.
[16] R. Selvarangan,et al. Cross-reactive antibody immunity against SARS-CoV-2 in children and adults , 2021, Cellular & Molecular Immunology.
[17] M. Salvi,et al. Protein kinase CK2: a potential therapeutic target for diverse human diseases , 2021, Signal Transduction and Targeted Therapy.
[18] Jared G. Galloway,et al. Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs , 2021, Cell Reports.
[19] Fridtjof Lund-Johansen,et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.
[20] Andreas Greinacher,et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.
[21] Christian C Toquica Gahona,et al. Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19 , 2021, Cureus.
[22] M. Tarantino,et al. Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine , 2021, Journal of blood medicine.
[23] Chaok Seok,et al. Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane , 2021, Journal of chemical theory and computation.
[24] R. Pinapati,et al. Immunoreactive peptide maps of SARS-CoV-2 , 2021, Communications biology.
[25] D. Ho,et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite , 2021, bioRxiv.
[26] Minoru Kanehisa,et al. KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..
[27] Limin Wang,et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis , 2020, BMC Infectious Diseases.
[28] M. Ghany,et al. Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care , 2020, Hepatology.
[29] Elizabeth B White,et al. Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.
[30] Yu Hu,et al. Thrombocytopenia and thrombosis in hospitalized patients with COVID-19 , 2020, Journal of Hematology & Oncology.
[31] Q. Ye,et al. Kidney involvement in COVID‐19 and its treatments , 2020, Journal of medical virology.
[32] Chaok Seok,et al. Structure, Dynamics, Receptor Binding, and Antibody Binding of Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane , 2020, bioRxiv.
[33] D. Lewis,et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives , 2020, Nature Reviews Cardiology.
[34] D. Kanduc. From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry , 2020, Antibodies.
[35] Andrew R. Leach,et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.
[36] J. Tate,et al. Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] A. Sette,et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.
[38] Y. Li,et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[39] L. Samaranayake,et al. Loss of taste and smell , 2020, British Dental Journal.
[40] Nathan R Kern,et al. Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane , 2020, bioRxiv.
[41] Shaun Rawson,et al. Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.
[42] Fang Li,et al. Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.
[43] W. Brady,et al. Cardiovascular complications in COVID-19 , 2020, The American Journal of Emergency Medicine.
[44] Yuan Yu,et al. Thrombocytopenia and its association with mortality in patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[45] C. Eastin,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.
[46] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[47] Xiaojuan He,et al. Low Level Antibodies Against Alpha-Tropomyosin Are Associated With Increased Risk of Coronary Heart Disease , 2020, Frontiers in Pharmacology.
[48] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[49] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.
[50] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[51] Daniel T. Montoro,et al. A human ciliopathy reveals essential functions for NEK10 in airway mucociliary clearance , 2020, Nature Medicine.
[52] Joel Nothman,et al. SciPy 1.0-Fundamental Algorithms for Scientific Computing in Python , 2019, ArXiv.
[53] M. Bronstein,et al. Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning , 2019, Nature Methods.
[54] B. Agrawal. Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections , 2019, Front. Immunol..
[55] Alessandro Sette,et al. The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..
[56] J. Despotovic. Emerging Therapies in Immune Thrombocytopenia , 2018 .
[57] Y. Shoenfeld,et al. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction , 2018, Cellular & Molecular Immunology.
[58] J. Kelton,et al. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia , 2016, British journal of haematology.
[59] C. Pecquet,et al. The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin , 2017, Front. Endocrinol..
[60] Alexandre M. J. J. Bonvin,et al. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes , 2016, Bioinform..
[61] Alexander D. MacKerell,et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field , 2015, Journal of chemical theory and computation.
[62] Jiye Shi,et al. SAbDab: the structural antibody database , 2013, Nucleic Acids Res..
[63] S. Miller,et al. Virus infection, antiviral immunity, and autoimmunity , 2013, Immunological reviews.
[64] D. Kuter. The biology of thrombopoietin and thrombopoietin receptor agonists , 2013, International Journal of Hematology.
[65] S. Francis. The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP. , 2010, Circulation research.
[66] J. Corbin,et al. cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.
[67] Jianpeng Ma,et al. CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..
[68] Geoffrey J. Barton,et al. Jalview Version 2—a multiple sequence alignment editor and analysis workbench , 2009, Bioinform..
[69] E. Birney,et al. Pfam: the protein families database , 2013, Nucleic Acids Res..
[70] Taehoon Kim,et al. CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..
[71] V. Georgiev,et al. National Institute of Allergy and Infectious Diseases, NI , 2008 .
[72] Leszek Rychlewski,et al. The challenge of protein structure determination—lessons from structural genomics , 2007, Protein science : a publication of the Protein Society.
[73] C. McCanny. Lack of evidence , 2006, British Dental Journal.
[74] F. W. Hoffbauer. Liver disease , 2005, The American Journal of Digestive Diseases.
[75] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[76] 中島 務,et al. マウス蝸牛における cyclic GMP-dependent protein kinase-I の発現 , 2005 .
[77] J. Skolnick,et al. TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.
[78] Takashi Kato,et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[79] F. Hofmann,et al. A Stimulatory Role for cGMP-Dependent Protein Kinase in Platelet Activation , 2003, Cell.
[80] W. Gorczyca,et al. [cGMP-dependent protein kinases]. , 2003, Postepy higieny i medycyny doswiadczalnej.
[81] S. Lohmann,et al. Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth Muscle* , 2000, The Journal of Biological Chemistry.
[82] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[83] H. Watarai,et al. Neutralization of Biological Activity and Inhibition of Receptor Binding by Antibodies Against Human Thrombopoietin , 1998, Stem cells.
[84] W R Taylor,et al. Residual colours: a proposal for aminochromography. , 1997, Protein engineering.
[85] M. Sanner,et al. Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.
[86] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[87] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[88] S. Nosé,et al. Constant pressure molecular dynamics for molecular systems , 1983 .
[89] A. Chobanian,et al. Cardiovascular Complications , 2007 .
[90] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[91] A. Szent-Györgyi. Calcium regulation of muscle contraction. , 1975, Biophysical journal.